A WKYMVm-containing combination elicits potent anti-tumor activity in heterotopic cancer animal model

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Kim, Sang Doo ^a,b   Lee, Ha Young ^a,b   Shim, Jae Woong ^a   Kim, Hak Jung ^a,b   Baek, Suk Hwan ^c   Zabel, Brian A ^d   Bae, Yoe Sik ^a,b  

^a Sungkyunkwan University   (South Korea)

^b Dong A University   (South Korea)

^c Yeungnam University College of Medicine   (South Korea)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; DENDRITIC CELL VACCINE; FAS ANTIGEN; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 12; TRYPTOPHYLLYSYLTYROSYLMETHIONYLVALYL DEXTRO METHIONINE; UNCLASSIFIED DRUG; CANCER VACCINE; CYTOKINE; IMMUNOLOGICAL ADJUVANT; OLIGOPEPTIDE; TRP LYS TYR MET VAL MET; TRP-LYS-TYR-MET-VAL-MET;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; LUNG METASTASIS; MALE; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL RATE; T CELL DEPLETION; TUMOR VOLUME; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; COLON TUMOR; DENDRITIC CELL; DISEASE MODEL; DRUG INTERACTION; IMMUNOLOGY; METABOLISM; METASTASIS; PATHOLOGY;

ANIMALIA; MUS;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; FLUOROURACIL; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; OLIGOPEPTIDES; SURVIVAL RATE;

EID: 84856249715     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030522     Document Type: Article

References (35)

1. Ciavarella S, Milano A, Dammacco F, Silvestris F, (2010) Targeted therapies in cancer. BioDrugs 24: 77-88.
2. Alymani NA, Smith MD, Williams DJ, Petty RD, (2010) Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation. Eur J Cancer 46: 869-879.
3. Kaye SB, (1998) New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 78 (Suppl 3): 1-7.
4. Liu HC, Chen GG, Vlantis AC, Tong MC, van Hasselt CA, (2008) Chemotherapy for laryngeal cancer-an apoptotic approach. Curr Drug Targets 9: 878-886.
5. Mellman I, Steinman RM, (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106: 255-258.
6. Steinman RM, (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271-296.
7. Steinman RM, Hemmi H, (2006) Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 311: 17-58.
8. Baek SH, Seo JK, Chae CB, Suh PG, Ryu SH, (1996) Identification of the peptides that stimulate the phosphoinositide hydrolysis in lymphocyte cell lines from peptide libraries. J Biol Chem 271: 8170-8175.
9. Seo JK, Choi SY, Kim Y, Baek SH, Kim KT, et al. (1997) A peptide with unique receptor specificity: stimulation of phosphoinositide hydrolysis and induction of superoxide generation in human neutrophils. J Immunol 158: 1895-1901.
10. Bae YS, Kim Y, Kim JH, Lee TG, Suh PG, et al. (2000) Independent functioning of cytosolic phospholipase A2 and phospholipase D1 in Trp-Lys-Tyr-Met-Val-D-Met-induced superoxide generation in human monocytes. J Immunol 164: 4089-4096.
11. Kim SD, Kim JM, Jo SH, Lee HY, Lee SY, et al. (2009) Functional expression of formyl peptide receptor family in human NK cells. J Immunol 183: 5511-5517.
12. Yang D, Chen Q, Gertz B, He R, Phulsuksombati M, et al. (2002) Human dendritic cells express functional formyl peptide receptor-like-2 (FPRL2) throughout maturation. J Leukoc Biol 72: 598-607.
13. Bae YS, Kim Y, Kim Y, Kim JH, Suh PG, et al. (1999) Trp-Lys-Tyr-Met-Val-D-Met is a chemoattractant for human phagocytic cells. J Leukoc Biol 66: 915-922.
14. Lee HY, Jo SH, Lee C, Baek SH, Bae YS, (2006) Differential production of leukotriene B4 or prostaglandin E2 by WKYMVm or serum amyloid A via formyl peptide receptor-like 1. Biochem Pharmacol 72: 860-868.
15. Le Y, Gong W, Li B, Dunlop NM, Shen W, et al. (1999) Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J Immunol 163: 6777-67784.
16. Christophe T, Karlsson A, Dugave C, Rabiet MJ, Boulay F, et al. (2001) The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J Biol Chem 276: 21585-21593.
17. He R, Tan L, Browning DD, Wang JM, Ye RD, (2000) The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor. J Immunol 165: 4598-4605.
18. Yamaki T, Uede T, Kikuchi K, (1990) Cellular mechanisms of tumor rejection in rats. Nat Immun Cell Growth Regul 9: 1-25.
19. Aguirre-Ghiso JA, (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834-846.
20. Nguyen DX, Bos PD, Massagué J, (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284.
21. Mayo SC, Pawlik TM, (2009) Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol 3: 131-144.
22. Lee SJ, Zhou T, Choi C, Wang Z, Benveniste EN, (2000) Differential regulation and function of Fas expression on glial cells. J Immunol 164: 1277-1285.
23. Xu X, Fu XY, Plate J, Chong AS, (1998) IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res 58: 2832-2837.
24. Germann T, Rüde E, (1995) Interleukin-12. Int Arch Allergy Immunol 108: 103-112.
25. Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, et al. (2006) Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 211: 81-92.
26. Helms MW, Prescher JA, Cao YA, Schaffert S, Contag CH, (2010) IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 59: 1325-1334.
27. Smyth MJ, Hayakawa Y, Takeda K, Yagita H, (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2: 850-861.
28. Melief CJ, van der Burg SH, (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8: 351-360.
29. Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, et al. (2009) Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114: 596-599.
30. Charoensit P, Kawakami S, Higuchi Y, Yamashita F, Hashida M, (2010) Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice. Cancer Gene Ther 17: 512-522.
31. Seo JK, Bae YS, Song H, Baek SH, Kim BS, et al. (1998) Distribution of the receptor for a novel peptide stimulating phosphoinositide hydrolysis in human leukocytes. Clin Biochem 31: 137-141.
32. Melief CJ, (2008) Cancer immunotherapy by dendritic cells. Immunity 29: 372-383.
33. Henry CJ, Ornelles DA, Mitchell LM, Brzoza-Lewis KL, Hiltbold EM, (2008) IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol 181: 8576-8584.
34. Talmor M, Mirza A, Turley S, Mellman I, Hoffman LA, et al. (1998) Generation or large numbers of immature and mature dendritic cells from rat bone marrow cultures. Eur J Immunol 28: 811-817.
35. Kadhim SA, Bowlin TL, Waud WR, Angers EG, Bibeau L, et al. (1997) Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res 57: 4803-4810.